Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Rang în acțiuni #16450
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Preț acțiune
$4.64
Ultima sincronizare: 2022-09-12
Capitalizare de piață
$293.43M
Schimbare (1 zi)
0.87%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Adagio Therapeutics, Inc. (ADGI)

Categorie

Raport P/B pentru Adagio Therapeutics, Inc. (ADGI)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Adagio Therapeutics, Inc., raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru Adagio Therapeutics, Inc. din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH